Advantage Alpha Capital Partners LP Cuts Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Advantage Alpha Capital Partners LP lowered its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 45.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 25,098 shares of the biopharmaceutical company’s stock after selling 21,053 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Dynavax Technologies were worth $321,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Dynavax Technologies by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock valued at $14,750,000 after purchasing an additional 32,347 shares during the period. Bank of Montreal Can grew its holdings in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Dynavax Technologies by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock valued at $11,893,000 after acquiring an additional 39,513 shares during the period. Nordea Investment Management AB raised its stake in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the last quarter. Finally, Peregrine Capital Management LLC raised its stake in shares of Dynavax Technologies by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 654,620 shares of the biopharmaceutical company’s stock valued at $8,359,000 after acquiring an additional 11,687 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DVAX has been the topic of a number of research analyst reports. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $13.84 on Tuesday. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 76.89 and a beta of 1.23. The stock’s 50 day simple moving average is $13.24 and its two-hundred day simple moving average is $12.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. As a group, analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.